{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:26Z","timestamp":1740106946466,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05503-z","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T06:02:27Z","timestamp":1697608947000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aswani","family":"Thurlapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Weeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly J.","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deidra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelynn","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy E.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Velayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan K.","family":"Bakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"issue":"8","key":"5503_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"issue":"1","key":"5503_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5503_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1022268103136","volume":"22","author":"M Benjamin","year":"2003","unstructured":"Benjamin M, Reddy S, Brawley OW (2003) Myeloma and race: a review of the literature. Cancer Metastasis Rev 22(1):87\u201393","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"5503_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","volume":"158","author":"S Ailawadhi","year":"2012","unstructured":"Ailawadhi S, Aldoss IT, Yang D et al (2012) Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 158(1):91\u201398. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09124.x","journal-title":"Br J Haematol"},{"issue":"7","key":"5503_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","volume":"8","author":"S Ailawadhi","year":"2018","unstructured":"Ailawadhi S, Jacobus S, Sexton R et al (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8(7):67. https:\/\/doi.org\/10.1038\/s41408-018-0102-7","journal-title":"Blood Cancer J"},{"issue":"12","key":"5503_CR6","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/bloodadvances.2021006652","volume":"6","author":"LC Peres","year":"2022","unstructured":"Peres LC, Colin-Leitzinger CM, Teng M et al (2022) Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv 6(12):3767\u20133778. https:\/\/doi.org\/10.1182\/bloodadvances.2021006652","journal-title":"Blood Adv"},{"issue":"5","key":"5503_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679\u2013686. https:\/\/doi.org\/10.1182\/blood-2010-02-268862","journal-title":"Blood"},{"issue":"16","key":"5503_CR8","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/cncr.30747","volume":"123","author":"JR Schriber","year":"2017","unstructured":"Schriber JR, Hari PN, Ahn KW et al (2017) Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer 123(16):3141\u20133149. https:\/\/doi.org\/10.1002\/cncr.30747","journal-title":"Cancer"},{"doi-asserted-by":"crossref","unstructured":"Perrot A, Lauwers-Cances V, Cazaubiel T et al (2020) Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood 136:Suppl 1:39\u201339. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497118693644","key":"5503_CR9","DOI":"10.1182\/blood-2020-134538"},{"issue":"2","key":"5503_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132\u2013147","journal-title":"N Engl J Med"},{"issue":"2","key":"5503_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269\u2013277. https:\/\/doi.org\/10.1038\/leu.2013.247","journal-title":"Leukemia"},{"unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department of Health and Human Services. Nov. Accessed 28 January 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf","key":"5503_CR12"},{"issue":"12","key":"5503_CR13","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548","journal-title":"Lancet Oncol"},{"unstructured":"United States Census Bureau Quickfacts: South Carolina. Accessed April 7, 2023. https:\/\/www.census.gov\/quickfacts\/fact\/table\/SC\/PST045222","key":"5503_CR14"},{"issue":"17","key":"5503_CR15","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV et al (2020) Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 38(17):1928\u20131937. https:\/\/doi.org\/10.1200\/JCO.19.02515","journal-title":"J Clin Oncol"},{"issue":"24","key":"5503_CR16","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.2019000406","volume":"133","author":"NR Fillmore","year":"2019","unstructured":"Fillmore NR, Yellapragada SV, Ifeorah C et al (2019) With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood 133(24):2615\u20132618. https:\/\/doi.org\/10.1182\/blood.2019000406","journal-title":"Blood"},{"issue":"2","key":"5503_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","volume":"12","author":"J Dong","year":"2022","unstructured":"Dong J, Garacci Z, Buradagunta CS et al (2022) Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J 12(2):34. https:\/\/doi.org\/10.1038\/s41408-022-00633-5","journal-title":"Blood Cancer J"},{"key":"5503_CR18","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1016\/S2152-2650(20)30956-3","volume":"20","author":"AK Nooka","year":"2020","unstructured":"Nooka AK, Kaufman JL, Rodriguez C et al (2020) MM-350: daratumumab (Dara) + lenalidomide\/bortezomib\/dexamethasone (Rvd) in african american\/black patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (Ndmm): subgroup analysis of griffin. Clin Lymphoma Myeloma Leuk 20:S308\u2013S309. https:\/\/doi.org\/10.1016\/S2152-2650(20)30956-3","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05503-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05503-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05503-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:04:03Z","timestamp":1704218643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05503-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5503"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05503-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was IRB approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}